Pegloticase

CHEMBL1237025 Phase 4 承認済み Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This enzyme therapy treats severe, chronic gout by converting uric acid into a substance the body can eliminate.

治療領域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This enzyme therapy treats severe, chronic gout by converting uric acid into a substance the body can eliminate.

Yes, Pegloticase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237025. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.